ELISpot assays revealed that the neoantigen-specific T-cell response for N1, N2, N6, and N9 was significantly enhanced after AdSVP-NAgmICC treatment (Fig. 2e and Supplementary Fig. 3b), with viral replication confirmed by CK19+ tumor cell-specific E1A expression detected by immunofluorescence staining (Fig. 2f). The gene discussed is DHTKD1; the disease is neoplasm.